<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Comparison of different in vivo antibody gene delivery platforms</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left"/>
    <th align="left">Synthetic DNA</th>
    <th align="left">mRNA</th>
    <th align="left">Viral vector</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Starting material</td>
    <td align="left">Plasmid DNA</td>
    <td align="left">Plasmid DNA</td>
    <td align="left">Plasmid DNA</td>
   </tr>
   <tr>
    <td align="left">Injected material</td>
    <td align="left">Plasmid DNA/by EP</td>
    <td align="left">mRNA in LNP</td>
    <td align="left">AAV, Ad vector</td>
   </tr>
   <tr>
    <td align="left">In vivo product</td>
    <td align="left">mAb, BsMAb</td>
    <td align="left">mAb, BsMAb</td>
    <td align="left">mAb, BsMAb</td>
   </tr>
   <tr>
    <td align="left">Transient</td>
    <td align="left">Yes</td>
    <td align="left">Yes</td>
    <td align="left">Yes; however, rare cases may integrate (AAV)</td>
   </tr>
   <tr>
    <td align="left">Cell compartment</td>
    <td align="left">Nucleus</td>
    <td align="left">Cytoplasm</td>
    <td align="left">Nucleus</td>
   </tr>
   <tr>
    <td align="left">Integration</td>
    <td align="left">None observed in humans</td>
    <td align="left">Low probability data early</td>
    <td align="left">Possible [
     <xref ref-type="bibr" rid="CR14">14</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Anti-vector immunity</td>
    <td align="left">No</td>
    <td align="left">No</td>
    <td align="left">Yes, serotype specific</td>
   </tr>
   <tr>
    <td align="left">Duration of a single administration</td>
    <td align="left">Weeks/months</td>
    <td align="left">Days/weeks</td>
    <td align="left">Months/years</td>
   </tr>
   <tr>
    <td align="left">Delivery route</td>
    <td align="left">ID, IM</td>
    <td align="left">IV, IM/ID</td>
    <td align="left">IM, IN, IV, IC, IO, IT</td>
   </tr>
   <tr>
    <td align="left">Tissue specificity/tropism</td>
    <td align="left">Local site of administration</td>
    <td align="left">Non-specific</td>
    <td align="left">Serotype dependent</td>
   </tr>
   <tr>
    <td align="left">Vector take</td>
    <td align="left">High in animals</td>
    <td align="left">High in preclinical</td>
    <td align="left">Variable</td>
   </tr>
   <tr>
    <td align="left">Human safety</td>
    <td align="left">Very safe, no SAEs in 1000s of individuals</td>
    <td align="left">Ongoing trials, SAEs reported [
     <xref ref-type="bibr" rid="CR15">15</xref>]
    </td>
    <td align="left">Safe but potential for integration (AAV)</td>
   </tr>
   <tr>
    <td align="left">Ease of manufacturing</td>
    <td align="left">Yes</td>
    <td align="left">Likely yes with caveats</td>
    <td align="left">Moderate</td>
   </tr>
   <tr>
    <td align="left">Cold-chain free</td>
    <td align="left">Yes</td>
    <td align="left">
     <p>Possible (with LNP)</p>
     <p>No (without LNP)</p>
    </td>
    <td align="left">No</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>AAV</italic> adenovirus-associated virus, 
   <italic>Ad</italic> adenovirus, 
   <italic>BsMAb</italic> bispecific mAb, 
   <italic>EP</italic> electroporation, 
   <italic>IC</italic> intracranial, 
   <italic>ID</italic> intradermal, 
   <italic>IM</italic> intramuscular, 
   <italic>IN</italic> intranasal, 
   <italic>IO</italic> intraocular (subretinal and intravitreal), 
   <italic>IT</italic> intrathecal, 
   <italic>IV</italic> intravenous, 
   <italic>LNP</italic> lipid nanoparticle, 
   <italic>mAb</italic> monoclonal antibody, 
   <italic>mRNA</italic> messenger RNA, 
   <italic>SAEs</italic> serious adverse events
  </p>
 </table-wrap-foot>
</table-wrap>
